GlaxoSmithKline Consumer Healthcare claims that a competitor is blowing smoke about the safety and efficacy of a rival smoking cessation product.
The drug company's Moon-based division filed a lawsuit in federal court Tuesday seeking an injunction against Nicodrops Inc., saying the California firm lacks proof that any herbal ingredient in Nicodrops is a safe or effective therapy for smoking cessation.
Glaxo says any company making such claims should be subject to the same review process that its nicotine replacement therapies went through at the Food and Drug Administration. Glaxo manufactures the smoking cessation products NicoDerm CQ patch, Nicorette gum and Commit lozenge.
"We've invested decades of work and considerable financial resources to ensure that our products are safe and are proven to work," said George Quesnelle, president of GSK Consumer Healthcare, North America. "When people are misled into using snake oil instead of products that are proven to work, they waste a critical opportunity to quit smoking."
Americans consumed more than $500 million in anti-smoking products sold over the counter last year, according to the market research firm ACNielsen, and Nicodrops started taking steps last year to establish itself in the U.S. market. The California company announced in December an agreement to place its non-nicotine smoking cessation lozenge on the shelves of more than 4,000 CVS stores.
Glaxo says Nicodrops contains three ingredients that haven't been proven effective in smoking cessation: ginseng, St. John's Wort and Valerian, according to the lawsuit.
The "Nico" prefix suggests that Nicodrops has nicotine when the product does not, Glaxo further alleges.
Glaxo also says Nicodrops has published false or misleading information about the safety and pricing of Glaxo's smoking cessation products.
Nicodrops said yesterday that it was standing behind its product and would aggressively defend against the lawsuit. The company, established in 1993, began marketing its product last year via the Internet.
"The suit filed by Glaxo-SmithKine has absolutely no basis to it," said Nicodrops President and Chief Executive Officer Christopher Calpito.
The complaint was filed in federal court because it addresses issues raised in the Lanham Act, which sets fair competition standards.

Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.